Cargando…
Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680433/ https://www.ncbi.nlm.nih.gov/pubmed/36412692 http://dx.doi.org/10.3390/neurolint14040070 |
_version_ | 1784834416647864320 |
---|---|
author | Wind, Joshua Park, Daniel Lansford, Todd Nunley, Pierce Peppers, Timothy Russo, Anthony Hassanzadeh, Hamid Sembrano, Jonathan N. Yoo, Jung Sales, Jonathan |
author_facet | Wind, Joshua Park, Daniel Lansford, Todd Nunley, Pierce Peppers, Timothy Russo, Anthony Hassanzadeh, Hamid Sembrano, Jonathan N. Yoo, Jung Sales, Jonathan |
author_sort | Wind, Joshua |
collection | PubMed |
description | Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m(2) (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis. |
format | Online Article Text |
id | pubmed-9680433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96804332022-11-23 Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion Wind, Joshua Park, Daniel Lansford, Todd Nunley, Pierce Peppers, Timothy Russo, Anthony Hassanzadeh, Hamid Sembrano, Jonathan N. Yoo, Jung Sales, Jonathan Neurol Int Article Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m(2) (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis. MDPI 2022-10-26 /pmc/articles/PMC9680433/ /pubmed/36412692 http://dx.doi.org/10.3390/neurolint14040070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wind, Joshua Park, Daniel Lansford, Todd Nunley, Pierce Peppers, Timothy Russo, Anthony Hassanzadeh, Hamid Sembrano, Jonathan N. Yoo, Jung Sales, Jonathan Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title | Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title_full | Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title_fullStr | Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title_full_unstemmed | Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title_short | Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion |
title_sort | twelve-month results from a prospective clinical study evaluating the efficacy and safety of cellular bone allograft in subjects undergoing lumbar spinal fusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680433/ https://www.ncbi.nlm.nih.gov/pubmed/36412692 http://dx.doi.org/10.3390/neurolint14040070 |
work_keys_str_mv | AT windjoshua twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT parkdaniel twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT lansfordtodd twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT nunleypierce twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT pepperstimothy twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT russoanthony twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT hassanzadehhamid twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT sembranojonathann twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT yoojung twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion AT salesjonathan twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion |